Johnson & Johnson: beats consensus in Q1
(CercleFinance.com) - Johnson & Johnson has reported adjusted net income that is up 11.
8% at 5.6 billion dollars for Q1 2018, or 2.06 dollars per share, while the market was expecting spot on two dollars.
The health group's revenues increased by 12.6% to 20 billion dollars, including an 8.4% increase in operating terms (i.e. excluding FX factors). When excluding changes in the group's consolidation scope as well, revenues rose by 4.3%.
For FY 2018, Johnson & Johnson maintains its target for adjusted EPS of between 8 dollars and 8.20 dollars, with revenues now expected to reach between 81 billion and 81.8 billion dollars (compared to a previous target range of 80.6 billion to 81.4 billion dollars).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
8% at 5.6 billion dollars for Q1 2018, or 2.06 dollars per share, while the market was expecting spot on two dollars.
The health group's revenues increased by 12.6% to 20 billion dollars, including an 8.4% increase in operating terms (i.e. excluding FX factors). When excluding changes in the group's consolidation scope as well, revenues rose by 4.3%.
For FY 2018, Johnson & Johnson maintains its target for adjusted EPS of between 8 dollars and 8.20 dollars, with revenues now expected to reach between 81 billion and 81.8 billion dollars (compared to a previous target range of 80.6 billion to 81.4 billion dollars).
Copyright (c) 2018 CercleFinance.com. All rights reserved.